Consistent with such molecular observations, increased eIF4E levels have been associated with malignant progression and poor therapeutic outcome [14,15,16], and in preclinical models, targeting eIF4E has been reported to inhibit tumor growth [13]. This evidence concerns the gene EIF4E and neoplasm.